Kornimate/medical-research-clean huggingface dataset:
stanford chronic pain self-management programme in danish chronic pain patients

Conditions: Chronic Pain

Summary: the effect of the stanford chronic pain self-management programme (cpsmp) is tested in a randomized controlled trial with enrollment of danish chronic pain patients. a total of 500 chronic pain patients is randomized into either an cpsmp intervention group or a control group. the cpsmp is brief patient education program consisting of 6 weekly sessions. two trained instructors teach a group of 8-16 chronic pain patients about managing pain. the instructors are not health professionals but chronic pain patient themselves. the program is highly structured and manualized. previous studies have shown beneficial effects of the cpsmp on pain, self-efficacy and well-being. hence we expect the cpsmp to have an effect on various domains. 1. symptom reduction - lower self-reported pain in the cpsmp group compared to controls 2. illness perception - the cpsmp group will differ from controls in illness perception and have higher disease related self-efficacy 3. sickness behavior - the cpsmp group will have fewer sick days and lower health care utilization (estimated by registerbased data)than controls 4. quality of life - the cpsmp group will report higher life satisfaction and less social isolation than controls


Eligibility criteria:
inclusion criteria: * pain in more than 3 months * self-reported pain \> 4.99 on 10 point likert scale * age \> 18 years old * able to understand, speak, and read danish exclusion criteria: * pain related to conditions that the patient are likely to consider more important than pain itself, e.g. pregnancy, cancer in acute phases * drug abuse, psychiatric or physical disease that would prevent participation in weekly sessions * drug abuse, psychiatric or physical disease that would disturb completion of group sessions

Keywords: chronic pain stanford chronic pain self-management programme patient education
metabolism associated with abdominal fat mass distribution

Conditions: Obese

Summary: objectives: the primary objective of this clinical trial is to characterize metabolic signatures associated with abdominal fat distribution in 40 women with different bmi 29-40 and different abdominal distribution of fat (visceral vs. sub-cutaneous fat). no intervention with a product is planned. the subjects will be given one high fat meal with commercial products (eggs, milk, cream, bread, fruits, cheese and cheese) on one test day to test the post-prandial metabolic response.


Eligibility criteria:
inclusion criteria: * bmi 29-40 kg/m2 * aged 25-45 exclusion criteria: * diagnosed metabolic disorder such as diabetes type 1 and 2, cardiovascular disease, metabolic syndrome * pregnancy * any pathology (infectious or other) having required an antibiotic therapy within 1 month prior to the beginning of the study. * any therapy (contraception apart) within the run-in period of one week before the test day. * subject who cannot be expected to comply with treatments and measures. * subject who is affected by any specific eating disorder * currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study. * subjects having recently undergone a weight loss of more than 3 kilos during the last 3 months

Keywords: obese women fat mass distribution metabolomic profiles
an observational study of avastin (bevacizumab) in patients with metastatic cancer of the colon or rectum

Conditions: Colorectal Cancer

Summary: this prospective observational study will evaluate the safety and efficacy of first-line avastin (bevacizumab) in combination with standard chemotherapy in routine clinical practice in patients with metastatic cancer of the colon and/or rectum. patients will be followed for the duration of their treatment and a 30-day follow-up after the last dose of study drug.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of metastases * at least one measurable metastatic lesion (as per recist criteria) * life expectancy of \> 12 weeks * eastern cooperative oncology group (ecog) performance status 0-2 * adequate hematological, renal and liver function exclusion criteria: * prior chemotherapy for metastatic disease * clinically significant cardiovascular disease * ongoing treatment with aspirin (325 mg/day) or other medications known to predispose for gastrointestinal ulceration * participation in an investigational trial in the previous 3 months * pregnant or lactating women * history of thrombotic or haemorrhagic disorders * evidence of bleeding diathesis or coagulopathy * uncontrolled hypertension * known hypersensitivity to avastin and any of its excipients, or any of the chemotherapies * evidence of any disease or disorder that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
correlation analysis of hearing thresholds, validated questionnaires and psychoacoustic measurements in tinnitus patients

Conditions: Tinnitus; Hearing Loss; Depression

Summary: objective: to evaluate the correlation between audiometric thresholds, pitch matching (pm), minimum masking level (mml), tinnitus handicap inventory (thi) and the beck depression inventory (bdi) in tinnitus patients. subjects: 48 patients with tinnitus as the main complaint from otosul, otorrinolaringologia sul-fluminense, volta redonda, rj, brasil and centro de tratamento e pesquisa em zumbido, belo horizonte, mg, brasil. method: subjects performed tonal audiometry, pitch matching (pm) and minimum masking level (mml) for tinnitus. they also fulfilled the tinnitus handicap inventory (thi) and beck depression inventory (bdi). data was statistically compared for correlation between audiometric thresholds, psycho-acoustic measures and questionnaires.


Eligibility criteria:
inclusion criteria: * tinnitus for more than 6 months * sensorineural hearing loss * normal otoscopy exclusion criteria: * conductive or mixed hearing losses * a-r, a-d, b and c tympanograms * tinnitus treatment in the last 6 months * pregnant woman * vestibular schwannoma

Keywords: tinnitus depression audiometry measurement
pain neuroscience education in diabetic neuropathy

Conditions: Pain, Neuropathic; Diabetic Nephropathy

Summary: to determine the effects of pain neuroscience education in diabetic neuropathy

pain neuroscience education (pne) has shown to have immediate effects on various clinical signs and symptoms associated with central sensitization. using a model of (innocuous, noxious and allodynia) pne can be used in combination with exercise therapy, especially treating patients in which the nervous system has become increasingly hypervigilant. teaching patients about the neuroscience of pain and lead to healthier and more positive attitudes and beliefs regarding chronic pain. pain in diabetic neuropathy restrict the activity participation and compromise their quality of life. pne will be helpful in such patients so decreasing pain can improve their quality of life.

Eligibility criteria:
inclusion criteria: * history of diabetic ≥ 5 years * hba1c higher and equal to 6.5 % * self-completed leeds assessment of neuropathic symptoms and signs pain scale (s-lanss) ≥ 12 * mini mental state examination (mmse) score ≥ 24 exclusion criteria: * known neurological disorder * foot ulcers/candidate of amputation * hearing impaired

Keywords: pain neuropathy diabetes
type 2 diabetes mellitus: new approaches to optimize medical care in general practice

Conditions: Type 2 Diabetes Mellitus

Summary: patients with type-2 diabetes mellitus have an higher risk developing secondary disorders. in an epidemiological longitudinal study of about 1.150 patients with type 2 diabetes mellitus we investigate determinants and predictors for long-term prognosis. the patients are recruited and supervised in practices of general practitioners of the administrative district of ludwigsburg/heilbronn (baden-württemberg, germany). in a subgroup of about 200 patients with a dissatisfactory metabolic status (hba1c \> 7,5%) a randomised interventional study is performed. the intervention comprises a telephone counseling by the medical secretary of each practice executed in a predefined period of time. the outcome parameters of interest are the change of hba1c, the development of secondary disorders and adverse events, quality of life and risk factor control, as well as hospitalization and mortality. the aim of the study was to develop an patient-centred instrument implementable in the routine medical care in order to enhance the prognosis of patients with type-2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * patient with type-2 diabetes mellitus attending the general practitioner's in the time from october to december 2008 * ability to take part in the study exclusion criteria: * nursing home resident * insufficient knowledge of the german language * palliative health care with limited life expectancy * emergency outpatient * all outpatients who attend the general practitioner by way of exception

Keywords: prevention health services research
combined nmes,fees and traditional swallowing rehabilitation in the treatment of stroke-related dysphagia

Conditions: Stroke

Summary: the investigators aimed to evaluate effects of combined nmes, fees and traditional swallowing rehabilitation in stroke patients with moderate-to-severe dysphagia.

neuromuscular electrical stimulation (nmes)and fiberoptic endoscopic evaluation of swallowing (fees) are both promising approaches to enhance swallowing recovery for dysphagic patients. however, there is no literature on the effectiveness of combined application of these modalities in the treatment of patients with poststroke dysphagia. the purpose of this study was to prospectively investigate whether combined nmes, fees and traditional swallowing rehabilitation can improve swallowing functions in patients with moderate-to-severe dysphagia after stroke.

Eligibility criteria:
inclusion criteria: * age between 20-85 years old * first-time stroke confirmed by computed tomography or magnetic resonance image * dysphagia \> 3 weeks, with preservation of the swallowing reflex * currently on a restricted diet, with a functional oral intake scale (fois) score of 5 or less * mini-mental state examination (mmse)\> 21 * no obvious mental depression, receptive aphasia or cognitive impairment exclusion criteria: * progressive cerebrovascular disease or other neurologic diseases * unstable cardiopulmonary status, serious psychologic disorder or epilepsy; * tumors, extensive surgery or radiotherapy of the head and neck region * cardiac pacemakers * swallowing therapy within 2 months before participation

Keywords: dysphagia,endoscopy, electrical stimulation,stroke
different doses and duration of low molecular weight heparin (parnaparin)in superficial vein thrombosis

Conditions: Thrombophlebitis

Summary: the optimal treatment of superficial venous thrombosis (svt) is still uncertain. though low molecular weight heparin (lmwh) is considered the treatment of choice, studies conducted so far do not give clear indications of the optimal dose and duration of treatment. this study aims to evaluate whether an intermediate therapeutic dose of lmwh (parnaparin) is more effective than a prophylactic dose and also to assess whether 10 rather than 30 days are sufficient for treatment.

outpatients with an episode of svt of the grand saphenous vein (for at least 4 cm), and/or svt of the small saphenous vein (for at least 4 cm), and/or svt of a collateral vein of the large saphenous vein of the thigh (for at least 4cm) are included in this prospective, randomised, double blind, national multicentre study. patients will be randomised into double-blind groups to receive (syringes will be identical in appearance) in consecutively numbered boxes: a - parnaparin, dose of 8,500 iu axa taken subcutaneously once a day for 10 days b - parnaparin, dose of 8,500 iu axa per day for 10 days followed by parnaparin 6,400 iu axa per day for the subsequent three weeks. c - parnaparin, dose of 4,250 iu axa per day for 30 days elastic compression treatment will be recommended with special stocking and/or elastic bandaging with compression to the ankles of 20-40 mmhg, where not contraindicated.

Eligibility criteria:
inclusion criteria: * weight \> 50 kg and less than 110 kg * svt of the grand saphenous vein for at least 4 cm * svt of the small saphenous vein for at least 4 cm * collateral svt of the large saphenous vein of the thigh for at least 4cm exclusion criteria: * svt of the grand saphenous vein reaching the saphenofemoral cross (within 3 cm) * svt of the small saphenous vein reaching the saphenopopliteal cross * documented proximal or distal dvt or pulmonary embolism * svt secondary to sclerotherapy * pregnancy and puerperium * uncontrolled arterial hypertension (systolic pressure \> 180 mmhg and diastolic pressure \> 110 mmhg) * active peptic ulcer * bacterial endocarditis * stroke in the previous 3 months * haemorrhagic diathesis * thrombocytopenia (platelets \< 100,000/ µl) * hypersensitivity to heparin or history of thrombocytopenia induced by heparin * creatinine \> 2 mg% (\> 180 µmol/l) * heparin therapy (any dose) or anticoagulant therapy for longer than the previous 72 hours * in-hospital development of svt * previous saphenectomy by any method * surgery in the previous 30 days * serious liver disease * use of dextran, mannitol, thrombolytic treatment, chronic use of nsaid and cortisone-based drugs. * active cancer or under chemotherapy or radiotherapy * thrombectomy of superficial vein involved * refusal to give informed consent

Keywords: superficial vein thrombosis thrombophlebitis lmwh parnaparin
rehabilitation trajectories

Conditions: Musculoskeletal Disease

Summary: the main aim of this multicentre cohort study is to provide evidence that can be used to improve continuity and quality in rehabilitation practice and rehabilitation processes across health care levels for patients with rheumatic and musculoskeletal diseases (rmds).

there is an urgent need to develop rehabilitation trajectories that ensure coordination and communication between health care levels, support of self-management and self-monitoring, and follow-up tailored to patients' needs. such trajectories should be based on evidence from current practice. the "rehabilitation trajectories" project will systematically explore and describe current practice of planned and implemented follow-up and self-management strategies in primary health care during the first year after rehabilitation for patients with musculoskeletal diseases. further, a newly developed core set of proms designed for evaluation of rehabilitation in rmds and a self-monitoring web-based system will be tested for feasibility. knowledge of patients' experiences and use of this self-monitoring system as a self-management and communication tool is needed in order to improve and integrate such e-technology in future care. the rehabilitation trajectory study is a multi-centre study, led by the national unit on rehabilitation in rheumatology and including participants at four rheumatology hospital departments and five specialized rehabilitation institutions. participants will thus be included from all four health regions in norway. the study has five points of assessment. in an electronic portal, delivered by checkware, patients will log in with their bank id and complete the core set of proms at admission, discharge, and 4, 8 and 12 months following discharge.

Eligibility criteria:
inclusion criteria: * admitted to rehabilitation at one of the nine participating rehabilitation centres with one of the following groups of diagnosis: inflammatory rheumatic disease, osteoarthritis, low back pain, neck/shoulder pain, generalized pain syndromes (including fibromyalgia), osteoporosis, connective tissue diseases (sle, lupus, myositis etc.), fractures with need of rehabilitation, or rehabilitation after orthopaedic surgery. good proficiency in oral and written norwegian language. access to internet and bankid. exclusion criteria: * cognitive impairment or severe mental illness.
comparative effect study between distal-proximal point association and local distribution point association in chemotherapy-induced nausea and vomiting

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: the purpose of this study is to clarify whether distal-proximal point association is more effective than partial match point association by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting .


Eligibility criteria:
inclusion criteria: 1. be diagnosed as cancer and need to accept chemotherapy. 2. the score of karnofsky ≥70 3. patients of either gender and older than 18 years 4. patients receiving chemotherapy both outpatients and inpatients 5. patients receiving chemotherapy either the first or multiple cycle, but the patient will be taken in only one time 6. to receive chemotherapy containing cisplatin(ddp≥75mg/m2) or joint chemotherapy programmes of anthracyclines(adriamycin≥40mg/m2 or epirubicin≥60mg/m2) 7. life expectancy≥ 6 months 8. willing to participate in the study and be randomized into one of the four study groups. exclusion criteria: 1. to receive radiotherapy and chemotherapy 2. gastrointestinal tumors 3. patients with serious liver disease or abnormal hepatorenal function (ast,act, and tbil are 3 times more than normal, bun and cr are 2 times more than normal) 4. presence of cardiac pacemaker 5. active skin infection 6. nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolyte disturbances) 7. patients unable to provide self-care or communication 8. nausea and/or vomiting resulting from mechanical risk factors (i.e., intestinal obstruction) 9. brain metastases 10. women in pregnant and lactating period

Keywords: to evaluate the effectiveness of acupucnture in the management of chemotherapy-induced nausea and vomiting
vancomycin pharmacokinetics in patients on peritoneal dialysis

Conditions: Peritoneal Dialysis-associated Peritonitis

Summary: vancomycin is the most commonly used empiric treatment for infectious peritonitis in patients on peritoneal dialysis. current dosing and monitoring for safety and efficacy is empiric, especially for those on rapid-cycling modalities. the goal of this study is to understand the pharmacokinetics of vancomycin in patients on rapid-cycling peritoneal dialysis modalities in order to derive an optimal dosing regimen.

peritoneal dialysis (pd) is a form of renal replacement therapy indicated for those with acute kidney injury or end stage renal disease. currently, two modalities of pd exist and is individualized based on patient and life-style specific factors. continuous ambulatory peritoneal dialysis (capd) allows 4 - 5 exchanges performed manually whereas automated peritoneal dialysis (apd) involves continuous, automated, cyclical exchanges performed by a device at home during the night. peritonitis is a common complication in pd and accounts for a large portion of hospital readmission and mortality. vancomycin is the most common antibiotic recommended and has notable gram-positive coverage used empirically during suspected peritonitis. despite widespread use, vancomycin lacks good pharmacokinetic characterization in pd. early pharmacokinetic studies using vancomycin were conducted predominantly in patients on capd on glucose-based prescriptions. data is non-existent in pd patients administered the novel dialysate solution icodextrin, or those treated with overnight apd. the impact of residual kidney function (rkf) on vancomycin in pd is also lacking. enhanced vancomycin clearance in rkf may result in under-dosing, while overdosing may result in nephrotoxicity and loss of clinically important rkf. the investigators will characterize the pharmacokinetic profile of vancomycin following a single intraperitoneal dose of vancomycin in icodextrin dialysate to non-infected pd patients and examine the relationship between rkf and vancomycin clearance using serum, dialysate and urine. the goal is to use this data in non-infected subjects to generate information to guide vancomycin dosing in patients on rapid-cycling pd modalities.

Eligibility criteria:
inclusion criteria: * adult male or females between 18 - 85 years old * stabilized on a pd regimen for \> 3 months prior to study initiation exclusion criteria: * clinically significant disease unrelated to renal impairment or deemed unfit by the investigator * allergy or hypersensitivity to vancomycin or icodextrin-containing dialysis solution * active peritonitis infection * previous intraperitoneal antibiotic treatment within 2 months * previous intravenous vancomycin treatment within 2 months * hemoglobin \< 9 g/dl * pregnant or breast-feeding women

Keywords: vancomycin pharmacokinetics pharmacodynamics automated peritoneal dialysis
urdu translation and validation of mlhfq

Conditions: Heart Failure

Summary: * to translate the minnesota living with heart failure questionnaire (mlhfq) questionnaire into urdu language of pakistan. * to determine the validity and reliability of cross cultural adapted and urdu translated mlhfq questionnaire version among hf patients.


Eligibility criteria:
inclusion criteria: * patients with chronic heart failure who sought treatment at the outpatient cardiology clinic. * who could read and write in urdu and english language and are willing to participate in the study. exclusion criteria: * decline consent * communication barriers or cognitive disorder as well as those with exacerbated condition and those who were not available for re-test were excluded from the study.
impact of hybrid closed-loop systems on sleep and psychosocial outcomes in youth with t1d and their parents

Conditions: Type 1 Diabetes

Summary: this study evaluates the impact of the hybrid closed-loop insulin delivery systems on sleep in youth with type 1 diabetes and their parents. activity watches, surveys and device downloads are used to evaluate sleep in these participants.

sleep is important for everyone, including youth with type 1 diabetes. new technology has shown improvements in glycemic variability, especially overnight. this study evaluates the impact of advanced hybrid closed-loop insulin delivery systems on sleep for both youth with type 1 diabetes and their parents. study measures include wearing an actigraphy watch and completing a sleep diary for 7 days and taking surveys on sleep and psychosocial measures. study measures occur prior to starting the hybrid closed-loop system, immediately after starting the system and at 3 and 6 months after starting the system.

Eligibility criteria:
inclusion criteria: * child diagnosed with type 1 diabetes for at least 3 months * child receives clinical care at the barbara davis center for diabetes * child starting an advanced hcl system as part of routine diabetes care * child currently living with a parent who is willing to complete surveys for this study * family able to read and speak english * parent lives at home with the child with type 1 diabetes * parent able to read and speak english exclusion criteria: * child has an active underlying sleep disorder, such as narcolepsy, insomnia or untreated sleep apnea * child participating in an interventional research protocol * child unable to complete study procedures * parent has an active underlying sleep disorder, such as narcolepsy, insomnia or untreated sleep apnea * parent unable to complete study procedures